CV Sciences Inc (OTCMKTS:CVSI) reported that the June 1 presentation from CFO Joseph Dowling is available for on-demand broadcasting at VirtualInvestorConferences.com. The presentation is made accessible 24/7 for 90 days. Advisors and investors may download shareholder resources from the virtual trade booth for the imminent three weeks. The firm invites institutional and individual investors, and also advisors to view presentation on VirtualInvestorConferences.com.
Recently, CV Sciences reported that it plans to meet the Food and Drug Administration in June 2017 to talk on its initial drug candidate, CVSI-007. In March 2017, the company reported its first web education platform intended to improve its brand education and advocacy via Experticity. The company elected Dr. Stephen M. Schmitz to its board to help advance its drug development plan forward to commercialization.
CV Sciences’ CEO and President Michael J. Mona, Jr. reported that they are extremely delighted to have Dr. Schmitz join their Board of Directors and look forward to his key contributions. His proven track record in the pharma industry and extensive medical background, including his regulatory and safety expertise, will be invaluable to company as it moves its drug development plan forward to commercialization.
Dr. Schmitz is a board approved physician with experience of almost 20 years in the pharmaceutical industry with thorough experience in dietary supplement safety, drug safety, clinical advancement and regulatory affairs.
He has been associated with numerous key pharmaceutical firms in the therapeutic areas of ophthalmology, neurosciences, orphan (rare) diseases and medical devices. While the emphasis of his pharma tenure has been on drug safety, he has also been into clinical development and worked as the medical monitor for many studies. CV Sciences reported that before venturing into the pharmaceutical market, Dr. Schmitz served in area of preventive medicine and practiced occupational and family medicine.
In the last trading session, the stock price of CV Sciences declined more than 3% to close the day at $0.285.